AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04957446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic
Description: Injectable implant containing microparticles of poly-L-lactic acid (PLLA)
Study NCT04957446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT04896086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRC-GENADJ0110-AP-NV
Description: Adjuplex is an adjuvant, a sterile, pyrogen-free adjuvant solution produced by VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline at a pH of 6.5 plus or minus 0.3. Adjuplex adjuvant will be mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B, 6A-6B, and 8A-8B.
Study NCT04896086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax
Description: Flucelvax is a cell-based vaccine which contains the same four influenza strains selected by the WHO, and has shown better safety and immunogenicity profiles than the traditional licensed seasonal egg based vaccine.
Study NCT04896086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-FLUMOS0111-00-VP (FluMos-v1)
Description: The VRC-FLUMOS0111-00-VP (FluMos-v1) vaccine is composed of engineered pentamer yeast C. albicans lumazine synthase assembled with 20 HA ectodomain trimers from the following influenza strains: Influenza A (H1: A/Idaho/07/2018, H3: A/Perth/1008/2019) and Influenza B (B/Victoria lineage: B/Colorado/06/2017, B/Yamagata lineage: B/Phuket/3073/2013)
Study NCT05201144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Oral Suspension
Description: Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
Study NCT05201144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volume of placebo
Study NCT04210648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Mobile app for self-managing emotional dysregulation
Study NCT06112665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG
Description: Patients receive Tofacitinib and Naproxene
Study NCT06112665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: Patients receive Tofacitinib and Naproxene
Study NCT05519098 — intervention group
Intervention type: DEVICE
Intervention: COLO-SW-1
Description: Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
Study NCT05765682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine Spinal
Description: spinal block using 60mg of mepivacaine
Study NCT05765682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Spinal
Description: spinal block using 10mg of bupivacaine
Study NCT05976555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)
Description: This is dose level 0 (de-escalation).
Study NCT05976555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
Description: This is dose level 1, the starting dose.
Study NCT05976555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)
Description: This is dose level 2.
Study NCT05976555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)
Description: This is dose level 3.
Study NCT05976555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose
Description: The maximum tolerated dose is yet to be determined.
Study NCT04608617 — intervention group
Intervention type: DEVICE
Intervention: Viz LVO (De Novo Number DEN170073)
Description: Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application.
Study NCT04608617 — intervention group
Intervention type: OTHER
Intervention: Baseline Effectiveness Cohort
Description: No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
Study NCT04755816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium intervention
Description: The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.
Study NCT04755816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical worsening intervention
Description: The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
Study NCT04755816 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational content
Description: Standard heart failure educational information and a daily symptom survey.
Study NCT06474624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio Rehabilitation program
Description: A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.
Study NCT06474624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling for 20-30 minutes
Description: Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.
Study NCT06474624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling a total of 4 cycles
Description: Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
Study NCT06532643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: anti-CD20/CD30-CAR-T cells
Description: Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed.
Study NCT06532643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Study NCT06532643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Study NCT05599750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional hernia repair
Description: Participants will undergo incisional hernia repair
Study NCT05400655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L9LS
Description: Administered subcutaneously.
Study NCT05400655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered subcutaneously.
Study NCT06394037 — intervention group
Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
Study NCT05932615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Description: TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Study NCT05932615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any Commercially Available Transcatheter Aortic Valve (CAV) System
Description: TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Study NCT05106881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Gait Enhancing and Motivating System (GEMS-H) Robot
Description: Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
Study NCT06296017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Extracorporeal Shock Wave Therapy
Description: Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
Study NCT06296017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger Finger Splint
Description: A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
Study NCT06296017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy+ Trigger Finger Splint
Description: Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
Study NCT05790889 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine
Description: Vaccine
Study NCT05790889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1 10μg adjuvated with 50μg Matrix-M
Description: Vaccine
Study NCT05790889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.2 5μg adjuvated with 50μg Matrix-M
Description: Vaccine
Study NCT04986202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831
Study NCT04986202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06171958 — intervention group
Intervention type: DRUG
Intervention: Iodine-containing Contrast Media
Description: Patients will receive or not receive ICM depending on their medical need.
Study NCT05817903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
Study NCT05817903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
Study NCT05817903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
Study NCT04803877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 40 MG
Description: For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
Study NCT04803877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 20MG
Description: For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
Study NCT04803877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle.
Study NCT04740983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliotherapy (a sole sun-bathing)
Description: 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
Study NCT00000928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling intervention
Description: Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
Study NCT06217939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early hydrocortisone
Description: For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.
Study NCT06217939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.
Study NCT06217939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label hydrocortisone
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
Study NCT06217939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label hydrocortisone
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
Study NCT05258240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality
Description: Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
Study NCT05258240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical Therapy
Description: Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
Study NCT06297187 — intervention group
Intervention type: DEVICE
Intervention: CUSA (Cavitronic Ultrasonic Surgical Aspirator)
Description: CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
Study NCT06285487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Program
Description: Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
Study NCT05241379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber UI System
Description: The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
Study NCT06421857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suturing
Description: laparoscopic cystectomy for endometrioma and hemostasis was done using suturing
Study NCT06421857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar electrocoagulation
Description: laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
Study NCT06325059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of renal progenitors
Description: Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivelestat sodium
Description: Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivelestat sodium placebo
Description: Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sivelestat sodium placebo
Description: Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone placebo
Description: Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
Study NCT06387823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone placebo
Description: Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
Study NCT05806463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's Time
Description: Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
Study NCT04955171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEOVU intravitreal injection
Description: BEOVU intravitreal injection
Study NCT05376384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound parameters
Description: Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
Study NCT05376384 — intervention group
Intervention type: PROCEDURE
Intervention: intraoperative parameters
Description: Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
Study NCT05114824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
Study NCT06044025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
Study NCT06044025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
Study NCT05389098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-Eating
Description: eat-hands type food mode
Study NCT05389098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual eating mode